Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
This phase III trial compares the effect of adding cetuximab to pembrolizumab versus pembrolizumab alone in treating patients with head and neck squamous cell carcinoma (HNSCC) that has come back after a period of improvement (recurrent) a…
- Avera Cancer Institute - Mitchell — Mitchell, South Dakota
- Avera Cancer Institute at Pierre — Pierre, South Dakota
- Sanford Cancer Center Oncology Clinic — Sioux Falls, South Dakota
- Avera Cancer Institute — Sioux Falls, South Dakota
- Sanford USD Medical Center - Sioux Falls — Sioux Falls, South Dakota